Journal
ARCHIVES OF DERMATOLOGY
Volume 146, Issue 3, Pages 300-304Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/archdermatol.2009.362
Keywords
-
Categories
Funding
- Intramural NIH HHS [ZID BC011317] Funding Source: Medline
Ask authors/readers for more resources
Background: Voriconazole is a triazole antifungal agent approved by the US Food and Drug Administration for serious fungal infections, including with Aspergillus, Fusarium, Pseudallescheria, and Scedosporium species. In initial clinical trials, approximately 2% of patients developed cutaneous reactions, including photosensitivity, cheilitis, and xerosis. Subsequent reports have implicated voriconazole as a cause of severe photosensitivity and accelerated photoaging, pseudoporphyria cutanea tarda, and aggressive squamous cell carcinoma. Observation: We report 5 melanoma in situ lesions in the setting of extreme photosensitivity associated with long-term voriconazole therapy. Conclusions: We recommend surveillance for skin cancer formation in all patients who require long-term voriconazole treatment, particularly those who manifest signs or symptoms of photosensitivity or chronic photo-damage. Further study of the mechanism underlying voriconazole photosensitivity and oncogenesis is warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available